Download PDF
Horm Metab Res 2014; 46(12): 889-896
DOI: 10.1055/s-0034-1389993
Review
© Georg Thieme Verlag KG Stuttgart · New York

From β-Catenin to ARM-Repeat Proteins in Adrenocortical Disorders

A. Berthon
1   Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics & Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
,
C. A. Stratakis
1   Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics & Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
› Author Affiliations
Further Information

Publication History

received 04 June 2014

accepted 03 September 2014

Publication Date:
08 October 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Armadillo-containing proteins (ACPs) are a large family of evolutionary conserved proteins, characterized by the tandem repeat copy of a 42 amino acids motif, which forms a 3 dimensional protein-protein interaction domain. This permits ACPs to interact with plenty of partners and consequently, most of these proteins have several independent cellular roles. Perhaps the most well-known protein of this family is β-catenin, which is crucial in the regulation of development and adult tissue homeostasis through its 2 independent functions, acting in cellular adhesion in addition to being a transcriptional co-activator. APCs have important functions in many tissues, but here we summarize the adrenocortical role of 2 well-described ACPs, β-catenin (CTNNB1), Adenomatous Polyposis Coli (APC), and discuss the possible role in the adrenal cortex of the most recently discovered, Armadillo-repeat containing 5 (ARMC5).

Key words

adrenocortical tumor - macronodular adrenal hyperplasia - APC - ARMC5 - β-catenin
 

  • References

  • 1 Huber AH, Nelson WJ, Weis WI. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell 1997; 90: 871-882
    CrossrefPubMedGoogle Scholar
  • 2 Tewari R, Bailes E, Bunting KA, Coates JC. Armadillo-repeat protein functions: questions for little creatures. Trends Cell Biol 2010; 20: 470-481
    CrossrefPubMedGoogle Scholar
  • 3 Chain PS, Grafham DV, Fulton RS, Fitzgerald MG, Hostetler J, Muzny D, Ali J, Birren B, Bruce DC, Buhay C, Cole JR, Ding Y, Dugan S, Field D, Garrity GM, Gibbs R, Graves T, Han CS, Harrison SH, Highlander S, Hugenholtz P, Khouri HM, Kodira CD, Kolker E, Kyrpides NC, Lang D, Lapidus A, Malfatti SA, Markowitz V, Metha T, Nelson KE, Parkhill J, Pitluck S, Qin X, Read TD, Schmutz J, Sozhamannan S, Sterk P, Strausberg RL, Sutton G, Thomson NR, Tiedje JM, Weinstock G, Wollam A, Detter JC. Genomics. Genome project standards in a new era of sequencing. Science 2009; 326: 236-237
    CrossrefPubMedGoogle Scholar
  • 4 Coates JC. Armadillo repeat proteins: beyond the animal kingdom. Trends Cell Biol 2003; 13: 463-471
    CrossrefPubMedGoogle Scholar
  • 5 Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J 2012; 31: 2714-2736
    CrossrefPubMedGoogle Scholar
  • 6 Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205
    CrossrefPubMedGoogle Scholar
  • 7 Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847
    CrossrefPubMedGoogle Scholar
  • 8 Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804
    CrossrefPubMedGoogle Scholar
  • 9 Yang-Snyder J, Miller JR, Brown JD, Lai CJ, Moon RT. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 1996; 6: 1302-1306
    CrossrefPubMedGoogle Scholar
  • 10 Sugioka K, Mizumoto K, Sawa H. Wnt regulates spindle asymmetry to generate asymmetric nuclear beta-catenin in C. elegans. Cell 2011; 146: 942-954
    CrossrefPubMedGoogle Scholar
  • 11 Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92: 3046-3050
    CrossrefPubMedGoogle Scholar
  • 12 Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003; 138: 424-429
    CrossrefPubMedGoogle Scholar
  • 13 Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008; 249: 756-775
    CrossrefPubMedGoogle Scholar
  • 14 Latronico AC, Chrousos GP. Neoplasms of the adrenal cortex. Clinical and basic aspects. Cancer Treat Res 1997; 89: 217-237
    PubMedGoogle Scholar
  • 15 McNicol AM. Diagnostic and molecular aspects of adrenal cortical tumors. Seminars Diagnost Pathol 2013; 30: 197-206
    PubMedGoogle Scholar
  • 16 Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Inter J Hypertens 2011; 2011: 162804
    PubMedGoogle Scholar
  • 17 Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 245-259
    CrossrefPubMedGoogle Scholar
  • 18 Almeida MQ, Stratakis CA. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 2010; 24: 907-914
    CrossrefPubMedGoogle Scholar
  • 19 Luconi M, Mannelli M. Xenograft models for preclinical drug testing: implications for adrenocortical cancer. Mol Cell Endocrinol 2012; 351: 71-77
    CrossrefPubMedGoogle Scholar
  • 20 Gicquel C, Baudin E, Lebouc Y, Schlumberger M. Adrenocortical carcinoma. Ann Oncol 1997; 8: 423-427
    CrossrefPubMedGoogle Scholar
  • 21 Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, Behrend M, Allolio B, Fassnacht M. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255: 363-369
    CrossrefPubMedGoogle Scholar
  • 22 Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R. Lack of beta-catenin affects mouse development at gastrulation. Development 1995; 121: 3529-3537
    PubMedGoogle Scholar
  • 23 Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, Lavery GG, Parker KL, Hammer GD. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 2008; 135: 2593-2602
    CrossrefPubMedGoogle Scholar
  • 24 King P, Paul A, Laufer E. Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages. Proc Natl Acad Sci USA 2009; 106: 21185-21190
    CrossrefPubMedGoogle Scholar
  • 25 Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, Taketo MM, Tissier F, Bertherat J, Lefrancois-Martinez AM, Martinez A, Val P. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human Mol Genet 2010; 19: 1561-1576
    CrossrefPubMedGoogle Scholar
  • 26 Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, Rene-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005; 65: 7622-7627
    CrossrefPubMedGoogle Scholar
  • 27 Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790
    CrossrefPubMedGoogle Scholar
  • 28 Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91-102
    CrossrefPubMedGoogle Scholar
  • 29 Doghman M, Cazareth J, Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 2008; 93: 3222-3225
    CrossrefPubMedGoogle Scholar
  • 30 Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefevre L, Guillaud-Bataille M, Beuschlein F, Tissier F, Bertherat J, Rizk-Rabin M, Ragazzon B. Silencing mutated beta-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PloS One 2013; 8: e55743
    CrossrefPubMedGoogle Scholar
  • 31 Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libe R, Rene-Corail F, Audebourg A, Vacher-Lavenu MC, Groussin L, Bertagna X, Dousset B, Bertherat J, Tissier F. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 2011; 96: E419-E426
    CrossrefPubMedGoogle Scholar
  • 32 Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reynies A, Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010; 70: 8276-8281
    CrossrefPubMedGoogle Scholar
  • 33 Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audebourg A, Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J, Tissier F. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17: 328-336
    CrossrefPubMedGoogle Scholar
  • 34 Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol 2008; 68: 264-270
    PubMedGoogle Scholar
  • 35 Stratakis CA. Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab 2003; 14: 404-410
    CrossrefPubMedGoogle Scholar
  • 36 Stratakis CA. Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer?. Nature Rev Endocrinol 2014; 10: 76-78
    CrossrefPubMedGoogle Scholar
  • 37 Tissier F. Classification of adrenal cortical tumors: what limits for the pathological approach?. Best Pract Res Clin Endocrinol Metab 2010; 24: 877-885
    CrossrefPubMedGoogle Scholar
  • 38 Gaujoux S, Tissier F, Groussin L, Libe R, Ragazzon B, Launay P, Audebourg A, Dousset B, Bertagna X, Bertherat J. Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. The Journal of clinical endocrinology and metabolism 2008; 93: 4135-4140
    CrossrefPubMedGoogle Scholar
  • 39 Boulkroun S, Samson-Couterie B, Golib-Dzib JF, Amar L, Plouin PF, Sibony M, Lefebvre H, Louiset E, Jeunemaitre X, Meatchi T, Benecke A, Lalli E, Zennaro MC. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology 2011; 152: 4753-4763
    Google Scholar
  • 40 Heikkila M, Peltoketo H, Leppaluoto J, Ilves M, Vuolteenaho O, Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 2002; 143: 4358-4365
    CrossrefPubMedGoogle Scholar
  • 41 Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, Samson-Couterie B, Zennaro MC, Plouin PF, Skah S, Plateroti M, Lefebvre H, Sahut-Barnola I, Batisse-Lignier M, Assie G, Lefrancois-Martinez AM, Bertherat J, Martinez A, Val P. WNT/beta-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Human Mol Genet 2014; 23: 889-905
    CrossrefPubMedGoogle Scholar
  • 42 Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T, Mantero F, Cicala MV, Quinkler M, Fallo F, Allolio B, Bernini G, Maccario M, Giacchetti G, Jeunemaitre X, Mulatero P, Reincke M, Zennaro MC. Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension 2014; 64: 354-361
    Google Scholar
  • 43 Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. Endocr Rel Cancer 2005; 12: 149-159
    CrossrefPubMedGoogle Scholar
  • 44 Berthon A, Martinez A, Bertherat J, Val P. Wnt/beta-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol 2012; 351: 87-95
    CrossrefPubMedGoogle Scholar
  • 45 Barzon L, Masi G, Fincati K, Pacenti M, Pezzi V, Altavilla G, Fallo F, Palu G. Shift from Conn’s syndrome to Cushing’s syndrome in a recurrent adrenocortical carcinoma. Eur J Endocrinol 2005; 153: 629-636
    CrossrefPubMedGoogle Scholar
  • 46 Abma EM, Kluin PM, Dullaart RP. Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Netherl J Med 2008; 66: 252-255
    PubMedGoogle Scholar
  • 47 Mussig K, Wehrmann M, Horger M, Maser-Gluth C, Haring HU, Overkamp D. Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension. J Endocrinol Invest 2005; 28: 61-65
    CrossrefPubMedGoogle Scholar
  • 48 Buchert M, Athineos D, Abud HE, Burke ZD, Faux MC, Samuel MS, Jarnicki AG, Winbanks CE, Newton IP, Meniel VS, Suzuki H, Stacker SA, Nathke IS, Tosh D, Huelsken J, Clarke AR, Heath JK, Sansom OJ, Ernst M. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet 2010; 6: e1000816
    CrossrefPubMedGoogle Scholar
  • 49 Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Molecular and cellular endocrinology 2012; 351: 66-70
    CrossrefPubMedGoogle Scholar
  • 50 Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A, Stratakis CA. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94: 2930-2937
    CrossrefPubMedGoogle Scholar
  • 51 Smith TG, Clark SK, Katz DE, Reznek RH, Phillips RK. Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 2000; 43: 1739-1742
    CrossrefPubMedGoogle Scholar
  • 52 Marchesa P, Fazio VW, Church JM, McGannon E. Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum 1997; 40: 1023-1028
    CrossrefPubMedGoogle Scholar
  • 53 Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libe R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res 2010; 16: 5133-5141
    CrossrefPubMedGoogle Scholar
  • 54 Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, Fragoso MC, Kuick R, Lerario AM, Simon DP, Soares IC, Starnes E, Thomas DG, Latronico AC, Giordano TJ, Hammer GD. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am J Pathol 2012; 181: 1017-1033
    CrossrefPubMedGoogle Scholar
  • 55 Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefevre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, Rene-Corail F, Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F, Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med 2013; 369: 2105-2114
    Google Scholar
  • 56 Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823
    CrossrefPubMedGoogle Scholar
  • 57 Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A, Libe R, Assie G, Espiard S, Drougat L, Ragazzon B, Bertherat J, Stratakis CA. Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation. J Clin Endocrinol Metab 2014; 99: E1113-E1119
    CrossrefPubMedGoogle Scholar
  • 58 Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, Hamet P, Bourdeau I, Zerbini MC, Pereira MA, Gomes GC, De Souza Rocha M, Chambo JL, Lacroix A, Mendonca BB, Fragoso MC. ARMC5 Mutations are a Frequent Cause of Primary Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab 2014; jc20134237
    PubMedGoogle Scholar
  • 59 Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal BE, Cutfield R, Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB, Torpy DJ, Scott HS. Armc5 Mutations Are Common in Familial Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab 2014; jc20141265
    PubMedGoogle Scholar
  • 60 Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nature Protocols 2009; 4: 363-371
    CrossrefPubMedGoogle Scholar
  • 61 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-1612
    CrossrefPubMedGoogle Scholar